Tolvaptan-induced hypernatremia related to low serum potassium level accompanying high blood pressure in patients with acute decompensated heart failure.
Hidetada FukuokaKoichi TachibanaYukinori ShinodaTomoko MinamisakaHirooki InuiKeisuke UenoSoki InoueKentaro MineKumpei UedaShiro HoshidaPublished in: BMC cardiovascular disorders (2020)
In tolvaptan treatment combined with standard therapy in ADHF patients, serum potassium level ≤ 3.8 mEq/L may be a determinant factor for hypernatremia development. Among hypokalemic patients, those with higher diastolic blood pressure on admission may be carefully managed to prevent hypernatremia.
Keyphrases
- blood pressure
- heart failure
- ejection fraction
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- emergency department
- prognostic factors
- type diabetes
- stem cells
- oxidative stress
- metabolic syndrome
- hypertensive patients
- mesenchymal stem cells
- skeletal muscle
- bone marrow
- atrial fibrillation
- hepatitis b virus